The impending SEC deregistration is a clear negative for U.S. OTC holders, likely reducing liquidity and potentially leading to delisting from OTCQB. Traders should monitor the OTCQB eligibility status and consider the reduced transparency as a risk factor. The net 1:3 share reduction is mechanical and does not alter fundamental value.
Price Chart
Executive Summary
COSCIENS Biopharma completed a 1:150 reverse stock split followed by a 50:1 forward split (net 1:3 reduction) and announced plans to file a Form 15 with the SEC to suspend its U.S. reporting obligations, effective July 6, 2026. Small shareholders (<150 shares) will receive US$1.60 cash per pre-consolidation share. The deregistration is a material negative for U.S. holders, as it reduces transparency and risks OTCQB delisting.
Key Facts
- Share capital amendment effective July 3, 2026: 1:150 consolidation immediately followed by 50:1 split, net 1:3 reduction in shares for holders of 150+ common shares.
- Holders of fewer than 150 pre-consolidation shares receive US$1.60 cash per share.
- Company intends to file Form 15 on July 6, 2026 to suspend SEC reporting obligations under the Exchange Act.
- No assurance shares will continue trading on OTCQB Venture Market after Form 15 filing.
- Common shares expected to trade on TSX on a post-amendment basis within two business days of July 3, 2026.
Financial Impact
No financial data provided; structural capital change with cash-out for small holders at US$1.60 per pre-consolidation share.
Risk Factors
- Loss of SEC reporting status may lead to OTCQB delisting, reducing liquidity and investor access.
- Reduced transparency and disclosure requirements increase information asymmetry and risk of adverse price moves.
- Cash-out for small shareholders may create selling pressure in the pre-consolidation period.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-032085 |
| Exhibit: ex99-1.htm | 0001493152-26-032085 |
| Document: 0001493152-26-032085-index-headers.html | 0001493152-26-032085 |
| Document: 0001493152-26-032085-index.html | 0001493152-26-032085 |
| Document: 0001493152-26-032085.txt | 0001493152-26-032085 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 6, 2026 16w ago | 6-K | $7.05 $5.14 | ▲ +27.09% | ▲ +27.94% | $6.10 (+13.48%) |
Jun 18, 2026 18w ago | 6-K | $2.26 $5.75 | ▲ +154.42% | ▲ +154.89% | $6.10 (+169.91%) |
May 12, 2026 24w ago | 6-K | $1.93 $2.03 | ▲ +5.18% | ▲ +5.79% | $6.10 (+216.06%) |
May 8, 2026 24w ago | 6-K | $1.91 $1.97 | ▲ +3.14% | ▲ +3.45% | $6.10 (+219.37%) |
Apr 20, 2026 27w ago | 6-K | $2.03 $1.87 | ▼ −7.88% | ▼ −12.08% | $6.10 (+200.49%) |
Mar 19, 2026 31w ago | EFFECT | $0.8600 $2.03 | ▲ +136.05% | ▲ +128.43% | $6.10 (+609.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers